Journal
HUMAN GENE THERAPY
Volume 26, Issue 8, Pages 506-517Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2015.072
Keywords
-
Categories
Funding
- Swedish Cancer Society
- Children's Cancer Foundation
- Swedish Medical Research Council
- Stockholm County Council (ALF)
- Cancer Society in Stockholm
- Swedish Society of Medicine
- Tobias Foundation
- Vinnova
- Swedish Foundation for Strategic Research (SSF)
- Karolinska Institutet
- Swedish Research Council (VR-Med)
- Swedish Research Council (EuroNanoMedII)
- Swedish Society of Medical Research (SSMF)
- EU IMI
- Estonian Research Council [PUT618]
- Parkinson"
- s UK [G-1109] Funding Source: researchfish
Ask authors/readers for more resources
The therapeutic potential of mesenchymal stromal cells (MSCs) is evident by the number of new and ongoing trials targeting an impressive variety of conditions. In bone and cartilage repair, MSCs are expected to replace the damaged tissue, while in other therapies they modulate a therapeutic response by the secretion of bioactive molecules. MSCs possess a phenotypic plasticity and harbor an arsenal of bioactive molecules that can be released upon sensing signals in the local milieu either directly or packaged in extracellular vesicles (EVs). The reported paracrine effects comprise many of the important functions of MSCs, including supporting hematopoietic stem cells in the bone marrow, promoting angiogenesis, and modulating the immune system. The major drawback in MSC therapy is the incomplete understanding of cell fate following systemic administration as well as the mechanisms by which these cells correct disease. In this review we discuss what is known about MSC engraftment, hemocompatibility, and immunomodulation, as well as the potential of bringing the MSC-EV field toward a clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available